济民药业,关爱无限 www.pidrug.com
香港济民药业微信二维码
198 9654 1773
当前位置:首页 > 药品资讯 > 精神科 > 卡西平Tegretol

卡西平Tegretol

[ 人气:141 | 日期: 2020-08-04 | 返回 | 打印 ]
卡西平Tegretol
药品名称:卡西平Tegretol
药品别名:卡马西平、卡马平片、卡马宾、癫妥锭、癫通锭、癫通长效膜衣锭
英 文 名:Tegretol
药品价格:$ 美国市场售价 88.24 美元
研发公司:
适 用 症:用于癫痫复杂部分性发作,三叉神经痛,情感精神性障碍。
型号规格:片剂,每片含有效成份100mg/200mg/400mg,每瓶100片装。
药品详情:

【卡西平Tegretol  简述】
 
    卡西平Tegretol又名卡马西平、卡马平片、卡马宾、癫妥锭、癫通锭、癫通长效膜衣锭,本品具有抗惊厥活性,对大脑皮质运动有高度选择性抑制作用,其作用可能在于阻断脑细胞的电压依赖性钠通道,从而阻止病灶放电的扩布。

卡西平Tegretol_香港济民药业

 
 
【卡西平Tegretol  适应症】
 
    本品适用于1.用于癫痫复杂部分性发作和全身强直阵挛性发作。还可作为难治型癫痫的辅助治疗。
 
    2.用于不耐受卡马西平或用其治疗无效的三叉神经痛。
 
    3.情感精神性障碍。
 
【卡西平Tegretol  规格】
 
    本品为片剂,每片含有效成份100mg/200mg/400mg,每瓶100片装。
 
【卡西平Tegretol  服用方法】
 
    开始剂量为每天300mg,以后可逐渐增量至每天900~3000mg,分3次服用,以达到满意的疗效。
 
【卡西平Tegretol  注意事项】
 
1.孕妇禁服。
 
2.用药前后应监测肝功能及血清钠浓度(因卡西平可导致低钠血症)。
 
3.酒精可使卡西平镇静作用增强。
 
4.停药应逐渐减量。
 
【卡西平Tegretol  不良反应】
 
1.常见头晕、头痛、复视。过量后可出现共济失调。
 
2.少见视力模糊、恶心、嗜睡、鼻炎、感冒样综合征、消化不良、皮疹和协调障碍等。


Tegretol(Carbamazepine)

 
Carbamazepine (CBZ), sold under the trade name Tegretol, among others, is a anticonvulsant medication used primarily in the treatment of epilepsy and neuropathic pain.[1] It is not effective for absence or myoclonic seizures.[1] It is used in schizophrenia along with other medications and as a second-line agent in bipolar disorder.[1] Carbamazepine appears to work as well as phenytoin and valproate.[3][needs update][4]
 
Common side effects include nausea and drowsiness.[1] Serious side effects may include skin rashes, decreased bone marrow function, suicidal thoughts, or confusion.[1] It should not be used in those with a history of bone marrow problems.[1] Use during pregnancy may cause harm to the baby; however, stopping the medication in pregnant women with seizures is not recommended.[1] Its use during breastfeeding is not recommended.[1] Care should be taken in those with either kidney or liver problems.[1]
 
Carbamazepine was discovered in 1953 by Swiss chemist Walter Schindler.[5] It was first marketed in 1962.[6] It is available as a generic medication.[7] It is on the World Health Organization's List of Essential Medicines, which lists the most effective and safe medicines needed in a health system.[8] The wholesale cost in the developing world is between 0.01 and US$0.07 per dose as of 2014.[9] In 2016, it was the 197th most prescribed medication in the United States, with more than 2 million prescriptions.[10]
 
Medical uses
 
Carbamazepine is typically used for the treatment of seizure disorders and neuropathic pain.[1] It is used off-label as a second-line treatment for bipolar disorder and in combination with an antipsychotic in some cases of schizophrenia when treatment with a conventional antipsychotic alone has failed.[1][11] It is not effective for absence seizures or myoclonic seizures.[1]
In the United States, the FDA-approved medical uses are epilepsy (including partial seizures, generalized tonic-clonic seizures and mixed seizures), trigeminal neuralgia, and manic and mixed episodes of bipolar I disorder.[12]
 
The drug is also claimed to be effective for ADHD.[13]
 
As of 2014, a controlled release formulation was available for which there is tentative evidence showing fewer side effects and unclear evidence with regard to whether there is a difference in efficacy.[14]
 
Adverse effects
 
In the US, the label for carbamazepine contains warnings concerning:
§  effects on the body's production of red blood cells, white blood cells, and platelets: rarely, there are major effects of aplastic anemia and agranulocytosis reported and more commonly, there are minor changes such as decreased white blood cell or platelet counts, but these do not progress to more serious problems.[2]
§  increased risks of suicide[2]
§  increased risks of hyponatremia and SIADH[2][15]
§  risk of seizures, if the person stops taking the drug abruptly[2]
§  risks to the fetus in women who are pregnant, specifically congenital malformations like spina bifida, and developmental disorders.[2][16]
 
Common adverse effects may include drowsiness, dizziness, headaches and migraines, motor coordination impairment, nausea, vomiting, and/or constipation. Alcohol use while taking carbamazepine may lead to enhanced depression of the central nervous system.[2]Less common side effects may include increased risk of seizures in people with mixed seizure disorders,[17] abnormal heart rhythms, blurry or double vision.[2] Also, rare case reports of an auditory side effect have been made, whereby patients perceive sounds about a semitone lower than previously; this unusual side effect is usually not noticed by most people, and disappears after the person stops taking carbamazepine.[18]
 
Interactions
 
Carbamazepine has a potential for drug interactions; caution should be used in combining other medicines with it, including other antiepileptics and mood stabilizers.[12] Lower levels of carbamazepine are seen when administrated with phenobarbital, phenytoin, or primidone, which can result in breakthrough seizure activity. Carbamazepine, as a CYP450 inducer, may increase clearance of many drugs, decreasing their concentration in the blood to subtherapeutic levels and reducing their desired effects.[19] Drugs that are more rapidly metabolized with carbamazepine include warfarin, lamotrigine, phenytoin, theophylline, and valproic acid.[12] Drugs that decrease the metabolism of carbamazepine or otherwise increase its levels include erythromycin,[20] cimetidine, propoxyphene, and calcium channel blockers.[12] Carbamazepine also increases the metabolism of the hormones in birth control pills and can reduce their effectiveness, potentially leading to unexpected pregnancies.[12]As a drug that induces cytochrome P450 enzymes, it accelerates elimination of many benzodiazepines and decreases their action.[21]
 
Valproic acid and valnoctamide both inhibit microsomal epoxide hydrolase (MEH), the enzyme responsible for the breakdown of carbamazepine-10,11 epoxide into inactive metabolites.[22] By inhibiting MEH, valproic acid and valnoctamide cause a build-up of the active metabolite, prolonging the effects of carbamazepine and delaying its excretion.
Grapefruit juice raises the bioavailability of carbamazepine by inhibiting CYP3A4 enzymes in the gut wall and in the liver.[2] Carbamazepine increases the processing of methadoneresulting in lower blood levels.[23]
 
Pharmacogenetics
 
Serious skin reactions such as Stevens–Johnson syndrome or toxic epidermal necrolysisdue to carbamazepine therapy are more common in people with a particular human leukocyte antigen allele, HLA-B*1502.[2] Odds ratios for the development of Stevens-Johnson syndrome or toxic epidermal necrolysis in people who carry the allele can be in the double, triple or even quadruple digits, depending on the population studied.[24][25] HLA-B*1502 occurs almost exclusively in people with ancestry across broad areas of Asia, but has a very low or absent frequency in European, Japanese, Korean and African populations.[2][26] However, the HLA-A*31:01 allele has been shown to be a strong predictor of both mild and severe adverse reactions, such as the DRESS syndrome form of severe cutaneous reactions, to carbamazepine among Japanese, Chinese, Korean, and Europeans.[25][27]
 
Mechanism of action
 
Carbamazepine is a sodium channel blocker.[28] It binds preferentially to voltage-gated sodium channels in their inactive conformation, which prevents repetitive and sustained firing of an action potential. Carbamazepine has effects on serotonin systems but the relevance to its antiseizure effects is uncertain. There is evidence that it is a serotonin releasing agent and possibly even a serotonin reuptake inhibitor.[29][30][31]
 
 




注:药品如有新包装,以新包装为准。以上资讯仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。

更多相关资讯:返回顶部
最新药品资讯
  • Venclyxto(维奈妥拉)联合MabThera治疗慢淋白血病,患者死亡风险降低!
  • Tagrisso(Osimertinib)在英国获批用于两种肺癌适应症的治疗
  • ziritaxestat治疗弥漫性皮肤系统性硬化症(dcSSc)2期概念验证研究成功!
  • 美国FDA批准GSK三联疗法:可同时治疗哮喘和慢阻肺
  • NBIb-1817一次性治疗帕金森病(PD)显著改善运动功能、延长ON时间
  • 口服抗生素tebipenem HBr治疗cUTI和AP关键III期临床成功,疗效不劣于ertapenem
  • 下一代选择性免疫调节剂IMU-838治疗多发性硬化症(RRMS)具有显著疗效,有良好的安全性和耐受性!
  • Fintepla(芬氟拉明)口服溶液治疗Dravet综合征相关癫痫的第三项3期研究结果:抽搐发作显著减少
  • 视神经脊髓炎谱系障碍(NMOSD)创新药Enspryng(satralizumab)获美FDA批准
  • Fasenra与标准类固醇同时治疗鼻息肉三期临床结果积极
  • Darzalex Faspro申请新适应症,治疗轻链(AL)淀粉样变性!
  • 地诺单抗(Xgeva,denosumab)治疗实体瘤骨转移疗效怎样?
  • 新药IDH1抑制剂Tibsovo治疗胆管癌效果怎么样?
  • 拜耳Nubeqa(达罗他胺)治疗非转移性去势抵抗性前列腺癌显著延长患者生存!
  • FDA对罗氏Tecentriq治疗三阴性乳腺癌研究发出警告!
  • 加码多发性硬化症!罗氏启动三项临床试验研究
  • Xeglyze说明书-价格-功效与作用-副作用
  • 赛诺菲/再生元Dupixent(达必妥®)显著延缓哮喘患者肺功能下降:疗效维持3年!
  • 默沙东止咳药gefapixant2项关键III期临床试验成功:咳嗽频率显著降低
  • Ryplazim(纤溶酶原)再次申请上市:首个先天性纤溶酶原缺乏症(C-PLGD)治疗药物!
  • 拜耳Adempas用于经PDE5i治疗反应不足的肺动脉高压(PAH)患者IV期临床成功
  • Midostaurin(米哚妥林)适应症是什么?优势在哪里?
  • 艾普利Apixaban可以在哪里买到正品?
  • 维奈妥拉/维奈托克(VENETOCLAX)怎么服用?注意事项是什么?
  • 芦可替尼Ruxolitinib治疗特应性皮炎效果好不好?
  • 巯嘌呤片(6-MP)Puri-nethol治疗急性白血病效果如何?
  • 晚期HCC患者能从Ramucirumab中获益吗?
  • 赫赛汀+拉帕替尼治疗乳腺癌效果更好
  • 欧盟批准Imfinzi(英飞凡):一线治疗广泛期小细胞肺癌(ES-SCLC)!
  • 第三代强效COMT抑制剂Ongentys(opicapone)用于治疗帕金森病(PD)的新药在日本上市!


  • 如您发现本网站有文字编辑或内容错误,请点击此处发送(需要安装有foxmail或outlook支持),


    或发邮件至:info@morecare.hk,香港济民药业感谢您的到访!


    欢迎您添加香港济民药业微信,或在公众号内留言。

    香港济民微信公众号
    • 香港济民药业友情链接
    • 友情链接

    联系我们:

    地址:
    Rm. 314, Sun Ling Plaza, 30 On Kui Street, Fanling, HONG KONG
    邮箱:
    info@pidrug.com
    电话:
    198 9654 1773
    粤ICP备17150936号
    香港济民药业官方网站
    • 关注我们 :
    • 香港济民药业微博
    • 关注香港济民药业博客
    • 香港济民药业微信公众号